Rhumbline Advisers Cuts Stock Holdings in Atrion Co. (NASDAQ:ATRI)

Rhumbline Advisers trimmed its position in shares of Atrion Co. (NASDAQ:ATRI) by 5.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,693 shares of the medical instruments supplier’s stock after selling 366 shares during the quarter. Rhumbline Advisers owned approximately 0.38% of Atrion worth $3,028,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ATRI. Quadrant Capital Group LLC acquired a new stake in Atrion in the 4th quarter valued at $36,000. EntryPoint Capital LLC acquired a new stake in Atrion during the 1st quarter worth $91,000. Comerica Bank boosted its stake in Atrion by 60.9% during the 1st quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 157 shares during the last quarter. Jump Financial LLC acquired a new stake in Atrion during the 4th quarter worth $234,000. Finally, Principal Financial Group Inc. acquired a new stake in Atrion during the 1st quarter worth $280,000. 66.19% of the stock is owned by hedge funds and other institutional investors.

Atrion Price Performance

Shares of NASDAQ:ATRI opened at $459.92 on Wednesday. The firm has a market capitalization of $809.46 million, a PE ratio of 43.23 and a beta of 0.69. The firm’s 50-day moving average is $458.52 and its two-hundred day moving average is $443.84. Atrion Co. has a 1 year low of $274.98 and a 1 year high of $503.24.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $48.77 million for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Atrion in a research report on Wednesday, September 11th. They set a “sell” rating on the stock.

Atrion Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.